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Abstract
Introduction: Secondary hyperparathyroidism (sHPT) is a common disorder in haemodialysed patients with chronic kidney disease (CKD). 
Cinacalcet increases the sensitivity of calcium receptor to the serum calcium, thus reducing serum parathormone (PTH) concentration. 
The aim of this study was to assess the safety and efficacy of six-month treatment with cinacalcet in haemodialysed CKD patients with 
sHPT in upper Silesia.
Material and methods: 71 haemodialysed CKD patients with sHPT (PTH > 300 pg/mL) were enrolled in this study. The target was to 
decrease PTH concentration below 300 pg/mL. PTH (ECL; Roche, Mannheim, Germany), calcium and phosphate concentration was as-
sessed before the first dose of cinacalcet and then after three and six months of treatment, before haemodialysis session. The results are 
shown as means and 95% confidence index.
Results: 58 patients completed the study. There was a significant decrease in serum PTH concentration from 1,138 pg/mL (931–1,345 pg/mL) to 
772 pg/mL (551–992 pg/mL) after three months of treatment (p < 0.0001) and to 635 pg/mL (430-839 pg/mL; p < 0.0001) after six months. 
The target PTH concentration was reached in 25% of the patients after three months and in 45% after six months of treatment. Cinacalcet 
was ineffective in decreasing serum PTH in 16 (28%) patients. There were no significant differences in serum calcium and phosphate 
concentration during the observation period. 
Conclusions: 
1. Cinacalcet decreases serum PTH concentration in most haemodialysed CKD patients with sHPT. 
2. In 28% of patients, resistance to treatment with cinacalcet was observed. 3. Cinacalcet treatment was well tolerated and caused only 
a few side effects. (Endokrynol Pol 2013; 64 (2): 176–181)
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Streszczenie
Wstęp: U hemodializowanych chorych na przewlekłą chorobą nerek (PChN) często występuje wtórna nadczynność przytarczyc. Cynakalcet 
zwiększa wrażliwość receptora wapniowego na wapń w surowicy krwi i powoduje obniżenie stężenia parathormonu (PTH) w surowi-
cy. Celem badania była ocena bezpieczeństwa i skuteczności sześciomiesięcznego leczenia preparatem cynakalcet hemodializowanych 
chorych na PChN z sHPT w województwie śląskim.
Materiał i metody: Badaniem objęto 71 hemodializowanych chorych na PChN z sHPT. Celem leczenia było zmniejszenie stężenia PTH 
w surowicy do wartości poniżej 300 pg/ml. U wszystkich chorych na początku badania, jak również po 3 i 6 miesiącach oznaczono stęże-
nia PTH (ECL; Roche, Mannheim, Niemcy), wapnia i fosforanów w surowicy przed zabiegiem hemodializy. Wyniki przedstawiono jako 
średnie i 95% przedział ufności.
Wyniki: Badanie ukończyło 58 osób. Leczenie cynakalcetem doprowadziło do znamiennego obniżenia stężenia PTH z 1138 pg/ml 
(931–1345 pg/ml) na początku badania do 772 pg/ml (551–992 pg/ml) po 3 miesiącach leczenia (p < 0, 0001), a po 6 miesiącach do 635 pg/ml 
(430–839 pg/ml; p < 0, 0001). Docelowe stężenie PTH w surowicy osiągnięto u 25% chorych po 3 miesiącach leczenia i u 45% chorych 
po 6 miesiącach leczenia. U 16 (28%) chorych leczenie cynakalcetem nie spowodowało zmniejszenia stężenia PTH w surowicy. Podczas 
leczenia preparatem cynakalcet nie obserwowano znamiennych zmian stężenia wapnia i fosforanów w surowicy. 
Wnioski: 
1. Cynakalcet obniża stężenie PTH w surowicy u większości hemodializowanych chorych na PChN z wtórną nadczynnością przytarczyc. 
2. U 28% chorych obserwuje się oporność na leczenie preparatem cynakalcet. 3. Leczenie preparatem cynakalcet było u większości chorych 
dobrze tolerowane i powodowało niewiele działań niepożądanych. (Endokrynol Pol 2013; 64 (2): 176–181)
Słowa kluczowe: cynakalcet, przewlekła niewydolność nerek, hemodializa, wtórna nadczynność przytarczyc
This study was supported by the Medical University of Silesia, contract number: KNW-1-033/P/2/0.
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Introduction
Mineral and bone disorders caused by secondary hy-
perparathyroidism (sHPT) are one of the most common 
abnormalities in haemodialysed patients with chronic 
kidney disease (CKD). This results in increased general 
and cardiovascular mortality in these patients [1–4].
Recently published data from clinical trials suggests 
that current sHPT pharmacotherapy might not be suf-
ficient to achieve KDIGO Guidelines for Chronic Kidney 
Disease-Mineral and Bone Disorders (CKD-MBD) [5, 10].
Cinacalcet is a type II calcimimetic [6, 7]. Such com-
pounds bind to the calcium receptor (CaR), leading to its 
positive allosteric modulation, which results in increased 
sensitivity of CaR to serum calcium. This leads to de-
creased parathormone (PTH) production by the para-
thyroid glands [6, 8, 9]. Cinacalcet is mostly used in stage 
5 CKD patients who require renal replacement therapy. 
Recent clinical trials suggest that cinacalcet (alone, 
or in addition to active vitamin D analogues) is effec-
tive in treating secondary hyperparathyroidism in 
haemodialysed CKD patients [11–14]. In the multicentre 
randomised ACHIEVE trial, the increased effectiveness 
of cinacalcet was confirmed with small doses of active 
vitamin D3 analogues vs. vitamin D alone in sHPT 
treatment. Also, in the ACHIEVE study such a treat-
ment showed greater reduction in the progression of 
cardiovascular and heart valve calcification compared 
to vitamin D alone [15, 16]. In other clinical trials, not 
only decreased  PTH concentration, but also a tendency 
to decreased parathyroid gland volume, has been de-
scribed as a consequence of cinacalcet treatment [17–21]. 
Long term efficiency of cinacalcet has also been con-
firmed — the target plasma PTH and ionised calcium 
concentrations, along with the decreased concentration 
of markers of bone metabolism (alkaline phosphatase, 
tartrate resistant acid phosphatase, N-terminal type-1 
collagen telopeptide), was sustained during a three-year 
observation in haemodialysed CKD patients [22, 23]. 
Cinacalcet is also effective in the treatment of 
primary hyperparathyroidism relapses after parathy-
roidectomy [24]. Some authors suggest that in selected 
patients with primary hyperparathyroidism, cinacalcet 
treatment may be an alternative to surgical treatment 
[25]. Nevertheless, cinacalcet treatment does not cause 
permanent parathyroid gland involution, nor perma-
nently suppress PTH secretion. In most cases, sHPT 
recurrence after cinacalcet withdrawal is observed. 
Despite the fact that in Poland cinacalcet has by 
now been used in sHPT treatment for several years, the 
clinical experience with this drug seems to be limited. 
This paper for the first time describes the results of 
cinacalcet therapy in a large cohort of haemodialysed 
patients in Poland. 
The aim of this study was to assess the efficacy and 
safety of six-month cinacalcet treatment in haemodia-
lysed CKD patients with sHPT in the Silesia region of 
Poland.
Material and methods
71 haemodialysed CKD patients (40 males, 31 females) 
with sHPT from nine different haemodialysis centres 
in Silesia were enrolled in this prospective, multicentre 
study. Mean age of patients was 53.3 ± 14.8 years, me-
dian time of renal replacement therapy was 32 months 
[interquartile range (IQR) — 28 months]. We included 
adult (> 18 years of age) haemodialysed CKD patients 
with sHPT (defined as serum PTH concentration > 300 
pg/mL) resistant to conventional treatment. Exclusion 
criteria were: age below 18 years, severe liver insuffi-
ciency, oversensitivity to any of the drug compounds, 
high probability of non-compliance and suspected short 
life expectancy on renal replacement therapy. 
Secondary hyperparathyroidism was treated with 
cinacalcet. Initial dose was 30 mg once daily and was 
modified if needed every four weeks depending on 
the serum intact-PTH concentration. The target was to 
decrease serum PTH concentration to 150–300 pg/mL. 
Maximal allowed dose of cinacalcet was 120 mg daily. 
In every patient, serum concentration of PTH, 
calcium and phosphate, as well as the parameters of 
peripheral blood morphology, were assessed before 
the first dose of cinacalcet and then after three and six 
months of treatment. The blood samples were collected 
before haemodialysis procedure in the middle of the 
week. After collection, blood samples were centrifuged, 
serum was aliquoted in 1ml test-tubes and then rapidly 
frozen at –70oC. Serum PTH concentration was assessed 
using the electrochemiluminescence (ECL) technique 
(Roche, Mannheim, Germany).
Statistical analyses were performed using the 
Statistica 10.0 PL software (StatSoft Polska, Krakow, 
Poland). Shapiro-Wilk test was used to test the variables 
distribution, Wilcoxon matched pairs test was used to 
assess the longitudinal (in-time) changes of variables. 
Mann-Whitney U-test was used to assess the differences 
between responders and non-responders and the cor-
relation coefficients were calculated using Spearman’s 
rank correlation. 
Results are shown as means with 95% confidence 
index (CI) in brackets, or as means with standard de-
viation in brackets, alternatively as median values with 
interquartile range (IQR) for variables with skewed 
distribution. Differences between measured parameters 
were considered significant when p < 0.05. The study 
protocol was accepted by the Medical University of 
Silesia Ethics Committee (KNW/0022/KB1/56/I/10 — 
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21.09.2010) and all patients gave informed consent to 
participate in the study. 
Results
From 71 enrolled patients, 58 (35 males, 23 females, 
mean age 53.8 ± 14.9 years) finished the study. Of the 
13 patients who were ruled out of the study, four died, 
two received kidney allograft, two patients discontin-
ued the study because of permanent decrease of serum 
PTH concentration below 150 pg/mL, two underwent 
parathyroidectomy, one patient refused to continue 
the study reporting paresthesia, one patient withdrew 
consent for the study, and one moved away from Silesia. 
The mean doses of cinacalcet after three and six 
months of treatment were 41.6 ± 16.8mg and 51.3 ± 
22.8 mg respectively.
In patients who finished the study, cinacalcet 
treatment caused a significant decrease of serum PTH 
from 1,138 pg/mL (931–1,345 pg/mL) at the baseline, to 
772 pg/mL (551–992 pg/mL) after three months of treat-
ment (p < 0.0001), and to 635 pg/mL (430–839 pg/mL; 
p < 0.0001) after six months of treatment (Table I). The 
mean decrease of serum PTH concentration after three and 
six months of treatment was 32.2% and 44.2% respectively.
The target PTH concentration was achieved in 25% 
of patients after three months of treatment and in 45% 
of patients after six months of treatment. It is important 
to stress the heterogeneous response to the cinacalcet 
treatment (Fig. 1). During the half-year observation in 
42 patients (72%), serum PTH concentration decreased, 
while in 16 cases (28%) there was an increase of serum 
PTH (n = 6), or serum PTH concentration was stable 
(n = 10; D PTH < 10%). The responders were significantly 
older than the non-responders [56.5 (52.0–61.1) v. 47.8 
(40.4–55.2) years of age, p = 0.04]. Moreover, there was 
a significant positive correlation between the magnitude 
of serum PTH decrease and patients’ age after three and 
Table I. The influence of cinacalcet treatment on serum PTH, calcium and phosphate concentrations in haemodialysed patients 
with secondary hyperparathyroidism
Tabela I. Wpływ leczenia cynakalcetem na stężenie PTH, wapnia i fosforanów w surowicy u hemodializowanych chorych 
z wtórną nadczynnością przytarczyc
Before  
treatment
After three  
months of 
treatment
After six  
months  
of treatment
p
0–3 months
p
3–6 months
p
0–6 months
Serum PTH  
concentration [pg/mL]
1,138  
(931–1,345)
772  
(551–992)
635  
(430–839)
< 0.0001 0.013 < 0.0001
Serum calcium  
concentration [mmol/L]
2.15  
(2.07–2.22)
2.11  
(2.04–2.17)
2.08  
(2–2.15)
0.23 0.38 0.12
Serum phosphate  
concentration [mmol/L]
2.02  
(1.87–2.18) 
1.97  
(1.81–2.14)
1.90  
(1.74–2.05)
0.27 0.38 0.20
PTH — parathormone
Figure 1. Serum PTH changes during cinacalcet treatment in 
individual patients who finished the observation
Rycina 1. Zmiany stężenia PTH w surowicy podczas leczenia 
cynakalcetem u poszczególnych chorych, którzy ukończyli badanie
six months of treatment (R = 0.35; p = 0.01 and R = 0.28; 
p = 0.03 respectively). There were no significant differ-
ences in the patients’ gender, length of renal replacement 
therapy, nor the serum PTH, calcium and phosphate 
concentrations at the baseline (Table II).
Serum calcium and phosphate concentrations were 
stable during the six months of cinacalcet treatment. 
Nevertheless, the mean daily dose of active vitamin 
D3 analogue (alfacalcidol) was increased from 0.26 mg 
(0.17–0.36 mg) at the baseline, to 0.39 mg (0.25–0.52 mg); 
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(p = 0.04) after six months, also the percentage of patients 
treated with alfacalcidol increased (Table III). Moreover, 
there was a significant (p = 0.02) decrease in the mean 
dose of aluminium hydroxide (Alusal) from 385 mg/day 
(170–410 mg/day) at the baseline, to 180 mg/day (15–350 
mg/day) after six months of treatment; also the percent-
age of patients treated with Alusal decreased. Conversely, 
the mean dose of calcium carbonate and the number of 
patients treated with this drug remained stable (Table III). 
Discussion
Cinacalcet was introduced to the treatment of second-
ary hyperparathyroidism in 2004. Many observational 
and randomised clinical trials (RCTs) with cinacalcet 
have been conducted so far [12–16, 26, 27]. This paper 
for the first time summarises the experience in cinacal-
cet treatment in such a large cohort of patients in the 
Upper Silesia region. 
As mentioned above, there was a decrease in se-
rum PTH concentration of 32.2% after three months 
of treatment and 44.2% after six months of treatment. 
These results are similar to those published in the most 
important recent trials concerning cinacalcet (Table IV). 
Cinacalcet treatment was generally well tolerated.
The main enrollment criterion in our study was 
serum PTH concentration exceeding 300 pg/mL and 
the target was to decrease the PTH concentration just 
below 300 pg/mL; however, the recent KDIGO guide-
lines suggest maintaining serum PTH concentration in 
haemodialysed patients in the range between 2–9 times 
higher than the ‘normal’ upper limit (i.e. ~150–600 pg/mL). 
The reason for such a wide accepted range of serum 
PTH concentration in these patients is that: “there are 
no RCTs showing that treatment to achieve a specific 
PTH level results in improved outcomes”. In addition, 
“there are no interventional RCTs that establish a ‘cause 
and effect’ relationship between the observed outcomes 
Table II. Comparison between patients in whom serum PTH concentration decreased (> 10% PTH decrease), and those in 
whom serum PTH did not decrease (serum PTH concentration increase or D PTH < 10%)
Tabela II. Porównanie chorych, u których doszło do obniżenia stężenia PTH w surowicy (spadek > 10%), z tymi u których 
stężenie PTH nie obniżyło się (wzrost stężenia PTH w surowicy, lub D PTH < 10%)
Patients with serum PTH  
decrease after treatment (n = 42)
Patients without serum PTH  
decrease after treatment (n = 16)
p
Mean age (years) 56.5 (52.0–61.1) 47.8 (40.4–55.2) 0.04
Sex — male/female (%) 27m/16f (63%m) 9m/7f (56%m) 0.56
Median of haemodialysis vintage (months) 31 (IQR:42) 32 (IQR:71) 0.33
Mean PTH concentration [pg/mL] 1,075 (878–1,271) 1,058 (771–1,334) 0.82
Mean calcium concentration [mmol/L] 2.14 (2.05–2.22) 2.17 (1.99–2.36) 0.64
Mean phosphate concentration [mmol/L] 1.97 (1.82–2.11) 2.17 (1.72–2.63) 0.50
PTH — parathormone; f — female; m — male
Table III. Doses of alfacalcidol, intestinal phosphate binders and the number of patients using those drugs during cinacalcet treatment
Tabela III. Dawki alfakalcydolu i leków wiążących fosforany w jelicie oraz liczba chorych je stosujących podczas leczenia cynakalcetem
Before treatment After three months  
of treatment
After six months  
of treatment
p  
0–3 months
p 
3–6 months
p 
0–6 months
Dose of alfacalcidol [mg/24 h] 0.26 (0.17–0.36) 0.32 (0.2–0.44) 0.39 (0.25–0.52) 0.16 0.16 0.04
Number of patients treated 
with alfacalcidol
30 (52%) 34 (59%) 40 (69%)
Dose of CaCO3 [g/24 h] 3.49 (2.68–4.30) 3.84 (2.95–4.72) 3.88 (3.04–4.72) 0.052 0.68 0.07
Number of patients treated 
with CaCO3
53 (91%) 55 (95%) 54 (93%)
Dose of aluminium hydroxide
[mg/24 h]
385 (170–605) 310 (80–540) 180 (15–350) 0.44 0.11 0.02
Number of patients treated 
with aluminium hydroxide
12 (21%) 8 (14%) 5 (9%)
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ate, sevelemer, aluminium hydroxide) and vitamin D3 
analogues, there were no significant differences in 
serum calcium nor phosphate concentration during 
a three-year observation period. Moreover, similarly to 
our study, there was a significant decrease in aluminium 
hydroxide dose in the study population [11].
So far there has been little published data concern-
ing the resistance to cinacalcet treatment in haemo-
dialysed patients with chronic kidney disease. Our 
study showed that the patients in whom cinacalcet 
was ineffective were considerably younger. One of the 
few documented factors potentially associated with 
cinacalcet resistance is nodular parathyroid hyperplasia 
(particularly if the volume of one or more hyperplasic 
glands exceeds 0.5 cm3 [28, 29]), or there is a multiplicity 
of enlarged glands [30]. It is difficult to establish how 
many of our patients had such enlarged parathyroid 
glands, as the ultrasonographic examination was not 
a routine procedure in patients enrolled in our study. 
The duration of renal replacement therapy also 
seems to be a factor predicting cinacalcet therapy resist-
ance. Yamamoto et al. [30] showed longer haemodialysis 
treatment in patients who did not reach target criteria 
for sHPT management (according to Japanese Society 
of Nephrology — serum PTH concentration below 
180 pg/mL). In our study, such a profound decrease 
in serum PTH secretion was not desired. Also serum 
PTH concentration was much higher (498–656.6 pg/mL 
— Yamamoto et al. [30] v. 1,138 pg/mL — this study), 
which may explain the differences between these stud-
ies. Of course, there is a possibility of non-compliance, 
during a part or the whole study, as a potential factor 
causing cinacalcet resistance in some of our patients. 
Table IV. Comparison of the results of cinacalcet treatment in haemodialysed CKD patients with secondary hyperparathyroidism 
in selected clinical trials
Tabela IV. Wyniki leczenia cynakalcetem hemodializowanych chorych na PChN z wtórną nadczynnością przytarczyc 
w wybranych badaniach klinicznych
Study Number of patients 
treated with 
cinacalcet
Observation length 
[months]
PTH concentrationat 
the beginning of the 
study [pg/mL]
Mean decrease of 
PTH concentration (%)
Mean dose of 
cinacalcet [mg]
Lindberg et al. [13] 294 6 526 40 60
OPTIMA [12] 224 6 505 46 56
ECHO [14] 1,865 12 605–954 38–58 44–54
ACHIEVE [15] 87 6 597 46 69
ADVANCE [16] 180 12 417 32 29
IMPACT p.o. [26] 72 6 510 43 32
Frazão J.M. et al. [27] 654 6 418 47 55
Current study 71 6 1,138 44 52
p.o. — the branch of IMPACT study with oral administration of cinacalcet
and the measured biochemical variables” [5]. However, 
in some patients with secondary hyperparathyroidisms 
(sHPT) the complex pharmacotherapy consisting of 
intestinal phosphate binders, vitamin D3 analogues 
and calcimimetics may lead to oversuppression of PTH 
secretion, which significantly increases the danger of 
development of the adynamic bone disease (in our 
study, despite the enrollment criterion, this happened in 
two patients — serum PTH dropped below 150 pg/mL). 
Adynamic bone disease may lead to increased fragility 
of the skeleton (the bones are prone to fractures) and 
accumulation of calcium in the organism. The excess 
amount of calcium may be responsible for increased 
calcifications in the soft tissue and vascular wall.
In many of the abovementioned studies, hypocal-
caemia and hypophosphatemia related to cinacalcet 
treatment have been described. In this study, serum 
calcium and phosphate concentrations remained sta-
ble during the whole half-year observation period. It 
is plausible to assume that this was caused by the fact 
that the study protocol, contrary to the majority of cina-
calcet trials, presumed flexible dosing of the intestinal 
phosphate binders (e.g. calcium carbonate) and active 
vitamin D3 analogues. Probably when a tendency to 
hypocalcaemia occurred, patients were administered 
higher (borderline significance — Table II) doses of 
calcium carbonate and active vitamin D3 analogues. 
Lower phosphate concentrations were also the cause 
of a more liberal manner of treatment with vitamin D3 
analogues (significant dose increase — Table II) and sig-
nificant aluminium hydroxide dose decrease (Table II). 
Similarly, in one of the few studies with flexible 
doses of intestinal phosphate binders (calcium carbon-
181
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Nevertheless, the patients were given their next packet 
of cinacalcet only after returning an emptied previous 
packet which, at least up to a point, should diminish 
the prevalence of such cases. 
Conclusions
1. Cinacalcet decreases serum PTH concentration in 
most haemodialysed CKD patients with secondary 
hyperparathyroidism. 
2. In 28% of patients, resistance to cinacalcet treatment 
was diagnosed. 
3. Cinacalcet treatment was well tolerated and caused 
only a few side-effects.
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